Findings
Cybersecurity is an integral part of medical device safety and effectiveness, and manufacturers are responsible for addressing it throughout the entire device lifecycle. The FDA considers a device’s cybersecurity as part of its benefit-risk assessment for both premarket and postmarket activities. A lack of robust cybersecurity controls can lead to patient harm, compromised device functionality, and breaches of data privacy. The dynamic nature of cybersecurity threats requires ongoing monitoring, risk management, and timely implementation of mitigation strategies.

Recommendations
Manufacturers should build cybersecurity into devices from the design phase (“secure by design”) and conduct a thorough risk analysis to identify and mitigate potential vulnerabilities. Premarket submissions should include comprehensive documentation of the device’s cybersecurity controls, a risk management plan, and a plan for postmarket surveillance and response. Manufacturers should establish a robust postmarket surveillance program to monitor for, identify, and address new cybersecurity threats in a timely manner. Clear and informative labeling is essential to help users understand and manage cybersecurity risks.

Regulatory Considerations
The FDA has the authority to take action against devices with inadequate cybersecurity that pose a risk to public health. The agency recommends that manufacturers use the Q-submission process to discuss specific cybersecurity questions related to their device submissions. Compliance with recognized standards and best practices for cybersecurity is strongly encouraged. Manufacturers must report certain cybersecurity incidents to the FDA as part of their postmarket reporting requirements. The FDA collaborates with other government agencies and stakeholders to promote a coordinated approach to medical device cybersecurity.